Skip to content

Arrowhead Research ARWR Return on equity

Return on equity at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-67.6%-20.3pp
ALN
Alnylam PharmaceuticalsALNY
66.9%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
-49.3%-0.8pp
Royalty Pharma logo
Royalty PharmaRPRX
8.4%-2.7pp
AbbVie logo
AbbVieABBV
89%+32.7pp
Revvity logo
RevvityRVTY
3.2%-0.5pp

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Calculated from Arrowhead Research’s reported figures.

Based on trailing twelve months.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's return on equity?
Arrowhead Research (ARWR) reported return on equity of -46.4% in Q1 2026.
How has Arrowhead Research's return on equity changed year-over-year?
Arrowhead Research's return on equity decreased by 88.0% year-over-year, from -24.7% to -46.4%.
What is the long-term trend for Arrowhead Research's return on equity?
Over 5 years (2020 to 2025), Arrowhead Research's return on equity has grown at a -53.9% compound annual growth rate (CAGR), from -23.9% to -0.5%.
What does return on equity mean?
How much profit the company earns on the money shareholders have invested.
How do you interpret return on equity?
Higher is better, but very high ROE can be manufactured by leverage — a thin equity base inflates the ratio. Read it next to debt-to-equity and ROIC to tell genuine returns from balance-sheet engineering.
How does return on equity compare across companies?
Comparable across peers, with the leverage caveat. Negative or near-zero equity makes ROE meaningless, so it is suppressed there.